Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Reddy's Adds To OTC Portfolio With Glenmark Deal

Acquires Anti-Allergy Brands In Russia, Ukraine, Kazakhstan And Uzbekistan

Executive Summary

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.

You may also be interested in...



Glenmark Builds US OTC Lineup In Wockhardt Deal

Glenmark acquires a portfolio of generic OTCs from Wockhardt marketed in US including famotidine 10- and 20-mgs; cetirizine 5- and 10-mgs; lansoprazole 15-mg delayed-release; and olopatadine hydrochloride 0.1% ophthalmic solution.

Glenmark Bolsters US OTC Portfolio With Wockhardt Products

Glenmark has moved to bolster its over-the-counter business in the US by acquiring a portfolio of approved generic OTC products from Wockhardt.

Acquisitions Are On Dr Reddy’s Menu

Dr Reddy’s indicates it is actively pursuing acquisitions, likely involving relatively smaller assets, across several key markets on the back of a “healthy” balance sheet. It is also progressing plans to position Russian COVID-19 vaccine Sputnik Light as a booster, which it believes could potentially be “part of life” hereon.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel